121 related articles for article (PubMed ID: 9699530)
1. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors.
Norberg T; Lennerstrand J; Inganäs M; Bergh J
Int J Cancer; 1998 Aug; 79(4):376-83. PubMed ID: 9699530
[TBL] [Abstract][Full Text] [Related]
2. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
[TBL] [Abstract][Full Text] [Related]
3. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
Linderholm BK; Lindahl T; Holmberg L; Klaar S; Lennerstrand J; Henriksson R; Bergh J
Cancer Res; 2001 Mar; 61(5):2256-60. PubMed ID: 11280795
[TBL] [Abstract][Full Text] [Related]
4. p53 determination in gynecological carcinomas: immunohistochemistry compared to luminometric immunoassay (LIA).
Heinze T; Greiner-Mai E; Lichtenegger W
Anticancer Res; 1999; 19(4A):2505-8. PubMed ID: 10470183
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.
Borg A; Lennerstrand J; Stenmark-Askmalm M; Fernö M; Brisfors A; Ohrvik A; Stål O; Killander D; Lane D; Brundell J
Br J Cancer; 1995 May; 71(5):1013-7. PubMed ID: 7734292
[TBL] [Abstract][Full Text] [Related]
6. P53 accumulation in primary breast cancer: a comparison between immunohistochemistry and a novel luminometric immunoassay.
Bombardieri E; Seregni E; Daidone MG; Benini E; Massaron S; Ferrari L; Di Fronzo G; Silvestrini R
Tumour Biol; 1998; 19(1):12-8. PubMed ID: 9422078
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of p53 genetic changes in colorectal cancer.
Kressner U; Inganäs M; Byding S; Blikstad I; Påhlman L; Glimelius B; Lindmark G
J Clin Oncol; 1999 Feb; 17(2):593-9. PubMed ID: 10080604
[TBL] [Abstract][Full Text] [Related]
8. cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer.
Szybka M; Zakrzewska M; Rieske P; Pasz-Walczak G; Kulczycka-Wojdala D; Zawlik I; Stawski R; Jesionek-Kupnicka D; Liberski PP; Kordek R
BMC Cancer; 2009 Aug; 9():278. PubMed ID: 19671129
[TBL] [Abstract][Full Text] [Related]
9. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study.
Hallak R; Mueller J; Lotter O; Gansauge S; Gansauge F; el-Deen Jumma M; Montenarh M; Safi F; Beger H
Int J Oncol; 1998 Apr; 12(4):785-91. PubMed ID: 9499437
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols.
Berns EM; De Witte HH; Klijn JG; Willman K; Look MP; Meijer-Van Gelder ME; Benraad TJ; Foekens JA
Anticancer Res; 1997; 17(4B):3003-6. PubMed ID: 9329586
[TBL] [Abstract][Full Text] [Related]
11. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.
Duddy PM; Hanby AM; Barnes DM; Camplejohn RS
J Mol Diagn; 2000 Aug; 2(3):139-44. PubMed ID: 11229518
[TBL] [Abstract][Full Text] [Related]
12. Correlation of mutation and immunohistochemistry of p53 in hepatocellular carcinomas in Korean people.
Lee SN; Park CK; Sung CO; Choi JS; Oh YL; Cho JW; Yoo BC
J Korean Med Sci; 2002 Dec; 17(6):801-5. PubMed ID: 12483005
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
14. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
Koul A; Bendahl PO; Borg A; Fernö M; Lidebring MF; Högberg T; Einarsson EL; Ridderheim M; Willén R
Int J Gynecol Cancer; 2002; 12(4):362-71. PubMed ID: 12144684
[TBL] [Abstract][Full Text] [Related]
15. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time.
Heinze T; Jonas S; Kärsten A; Neuhaus P
Anticancer Res; 1999; 19(4A):2501-3. PubMed ID: 10470182
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives.
Lohmann D; Ruhri C; Schmitt M; Graeff H; Höfler H
Diagn Mol Pathol; 1993 Mar; 2(1):36-41. PubMed ID: 8287224
[TBL] [Abstract][Full Text] [Related]
17. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers.
Norberg T; Klaar S; Lindqvist L; Lindahl T; Ahlgren J; Bergh J
Clin Chem; 2001 May; 47(5):821-8. PubMed ID: 11325884
[TBL] [Abstract][Full Text] [Related]
19. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
20. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers.
Takahashi M; Tonoki H; Tada M; Kashiwazaki H; Furuuchi K; Hamada J; Fujioka Y; Sato Y; Takahashi H; Todo S; Sakuragi N; Moriuchi T
Int J Cancer; 2000 Jan; 89(1):92-9. PubMed ID: 10719737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
